BioSpace News Archive

Vantage Galan 3T the First System in the MR Portfolio with Access to Advanced intelligent Clear-IQ Engine (AiCE)

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces an update for IDE196, a Protein Kinase C inhibitor, in its ongoing Phase 1/2 clinical trial entitled “A Phase 1/2 Study in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions”.

VitalTech, a rapidly growing market leader in Telehealth and Virtual Care, announced that it is offering health systems, physicians and their patients free Telehealth access* through their VitalCare® platform in an effort to fight the spread of COVID-19.

Data to be shared as a late-breaking oral presentation during the live virtual NKF conference

Golden Meditech Holdings Limited, a leading integrated healthcare enterprise in China, announced that its associate, Cellenkos, Inc. has submitted a clinical development proposal to the Biomedical Advanced Research and Development Authority to start a Phase 1/2 clinical trial with CK0802 for treatment of COVID-19 mediated acute respiratory distress syndrome.

SpringWorks Therapeutics, Inc. announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,590,087, directed to nirogacestat, the Company’s lead product candidate in development for patients with desmoid tumors and as a combination therapy for patients with multiple myeloma.

Oral Vaccines based on Proprietary VAAST™ Platform Offer Potential Key Advantages in Global Quest to Develop Coronavirus Vaccine

Viela Bio announced it will host a webcast and conference call on Wednesday, March 25, 2020 at 5:00 p.m. ET to discuss its fourth quarter and full year 2019 operating and financial results.

Expected regulatory pathway for episodic treatment of major depression remains unchanged with plan for one new additional efficacy study

Myriad Genetics, Inc. announced that the National Comprehensive Cancer Network updated its professional guidelines for prostate cancer to recommend biomarker-based testing for men with unfavorable intermediate and high-risk disease.